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ABSTRACT
Juvenile myelomonocytic leukemia is a childhood malignancy that lacks effective 
chemotherapies and thus has poor patient outcomes. PI3K p110δ has been found 
to promote hyperproliferation of cells expressing mutant Shp2. In this study, we 
tested the efficacy of a PI3Kδ inhibitor in mice expressing the Shp2 gain-of-function 
mutation, E76K. We found that in vivo treatment of mice led to significantly decreased 
splenomegaly, reduced frequency of bone marrow progenitor cells, and increased 
terminally differentiated peripheral blood myeloid cells. The survival of drug-treated 
mice was significantly prolonged compared to vehicle-treated controls, although mice 
from both groups ultimately succumbed to a similar myeloid cell expansion. PI3Kδ 
inhibitors are currently used to treat patients with relapsed lymphoid malignancies, 
such as chronic lymphocytic leukemia. The current findings provide evidence for 
using PI3Kδ inhibitors as a treatment strategy for JMML and potentially other myeloid 
diseases.
INTRODUCTION
Juvenile myelomonocytic leukemia (JMML) is an 
aggressive overproduction of cells in the myeloid lineage, 
affecting young children with a median age of 2 years, 
and is characterized by hypersensitivity to the cytokine 
granulocyte macrophage colony-stimulating factor 
(GM-CSF). Currently, allogeneic stem cell transplant 
remains the only curative treatment, with a 5-year 
event-free survival of only 50% [1, 2]. When studying 
gain-of-function (GOF) mutations in Shp2, which is 
the most common mutation found in JMML patients, 
we have previously focused on the downstream target 
phosphoinositide 3 kinase (PI3K). We found that genetic 
and pharmacologic inhibition of the hematopoietic-
specific catalytic subunit of PI3K, p110δ, is uniquely 
important in promoting GOF Shp2-induced leukemia [3]. 
The genetic inhibition of p110δ in vivo led to reduced 
splenomegaly, decreased phosphorylation of Akt and Erk, 
and decreased progenitor cell hypersensitivity to GM-
CSF in a Shp2D61Y/+;Mx1cre+ mouse model of JMML. 
Furthermore, pharmacologic inhibition of p110δ in vitro 
decreased phospho-Akt and -Erk and proliferation of 
Shp2D61Y/+ cells, as well as the GM-CSF hypersensitivity 
of mononuclear cells from primary JMML patient samples 
[3].
The PI3K p110δ inhibitor idelalisib was FDA-
approved in 2014 for patients with relapsed chronic 
lymphocytic leukemia and follicular lymphoma [4]. 
However, the effectiveness of p110δ inhibition in JMML, 
a disease that lacks effective chemotherapies, has not 
been studied. Therefore, following our promising results 
demonstrating reduced GM-CSF hypersensitivity and 
proliferation of GOF Shp2-expressing murine cells and 
primary JMML cells in vitro, we assessed the effect of 
PI3K p110δ inhibition on GOF Shp2-expressing mice in 
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vivo as the next step in exploring p110δ inhibition as a 
potential treatment strategy for JMML. We utilized the 
PI3K p110δ inhibitor GS-9820 (hereafter PI3Kδ inhibitor), 
which has superior pharmacokinetics in murine models 
(Dr. Stacey Tannheimer, personal communication) [5].
RESULTS
We treated Shp2E76K/+;LysMcre+ mice between 12 
and 20 weeks of age with 30mg/kg of PI3Kδ inhibitor 
or vehicle (0.5% w/v methylcellulose + 0.1% v/v 
Tween 80) BID via oral gavage for 21 days. This mouse 
model has previously been shown to develop a myeloid 
expansion that closely mimics human JMML and has an 
ideal treatment window of 12-20 weeks between disease 
development and death [6]. We used two separate cohorts 
of mice: the first cohort had seven mice per treatment 
group and was euthanized 16 hours following the final 
dose of PI3Kδ inhibitor; the second cohort had 15 mice 
per treatment group and was followed long-term for 
overall survival.
First, we evaluated mice directly after completing 
21 days of treatment (16 hours following final vehicle or 
PI3Kδ inhibitor dose). The PI3Kδ inhibitor-treated mice 
had significantly reduced spleen-to-body weight ratio in 
comparison to the vehicle-treated mice (Figure 1A). We 
measured the colony-forming ability of bone marrow 
low-density mononuclear cells (LDMNCs) in response 
to increasing concentrations of GM-CSF. 100,000 
LDMNCs from each mouse were plated in semi-solid 
methylcellulose media containing 0, 0.01, 0.1, or 10ng/
mL GM-CSF and colonies were counted 7 days later. 
LDMNCs isolated from PI3Kδ inhibitor-treated mice 
demonstrated similar GM-CSF hypersensitivity compared 
to the vehicle-treated mice, indicating that pharmacologic 
inhibition of PI3K p110δ does not permanently correct 
GM-CSF hypersensitivity of GOF Shp2-expressing cells 
(Figure 1B). To investigate how PI3Kδ inhibitor treatment 
induced the functional effect of reduced spleen size, we 
phenotypically analyzed the bone marrow, spleen, and 
peripheral blood for hematopoietic stem/progenitor cells 
(lineage-Sca1+cKit+, LSK) and for terminally differentiated 
hematopoietic cells. The frequency of LSK cells was 
significantly reduced in the bone marrow of PI3Kδ 
inhibitor-treated mice and trended lower in the spleen 
and peripheral blood (Figure 1C). When examining 
hematopoietic differentiation, we found no significant 
difference in myeloid progenitor populations (CMPs, 
GMPs, or MEPS, data not shown) or in the frequency 
of terminally differentiated CD4+, CD8+ (T cells), B220+ 
(B cells), and Gr1+Mac1+ (myeloid cells) in the bone 
marrow and spleen compartments (Figure 1D and 1E). 
However, the frequency of peripheral blood Gr1+Mac1+ 
cells was significantly increased in the PI3Kδ inhibitor-
treated mice compared to vehicle-treated mice (Figure 1F). 
Furthermore, the Mac1+ mean fluorescence intensity (MFI) 
in the peripheral blood was significantly higher in PI3Kδ 
inhibitor-treated mice (Figure 1G and 1H). Collectively, 
these findings suggest that PI3K p110δ inhibition induced 
stem/progenitor terminal differentiation and reduced the 
self-renewal and hyperproliferation of immature myeloid 
cells.
The second cohort of 15 mice per treatment group 
was followed for overall survival with peripheral blood 
counts assessed every 4 - 6 weeks. Each treatment group 
consisted of 6 male mice and 9 female mice, and groups 
were age-matched (average age was 114 days for the 
vehicle-treated mice and 109 days for the PI3Kδ inhibitor-
treated mice). Survival of the PI3Kδ inhibitor-treated mice 
was significantly prolonged compared to their vehicle-
treated counterparts (Figure 2A). Serial peripheral blood 
WBC counts were similar between the two groups until 
approximately 18 weeks following the start of treatment, 
when WBC counts in the vehicle-treated animals started 
increasing compared to the PI3Kδ inhibitor-treated mice 
(Figure 2B). Notably, the period of time of increasing 
WBC counts in the vehicle-treated animals coincided 
with the period of time when the survival curves started 
to separate (20 - 35 weeks). Later at 37 weeks, the drug-
treated mice also demonstrated an increase in WBC 
counts, which corresponded to this group’s cluster of 
deaths between 38 - 40 weeks. 
Whenever possible, moribund mice were euthanized 
for analysis to assess the cause of death. Although the 
PI3Kδ inhibitor-treated animals demonstrated prolonged 
survival, at the time of euthanasia, these animals 
demonstrated similar levels of splenomegaly and elevated 
peripheral leukocyte counts compared to the vehicle-
treated animals (Figure 2C and 2D). Furthermore, 
composition of the bone marrow and spleen in moribund 
animals was not significantly different between the two 
groups (Figure 2E and 2F). Most animals in both groups 
succumbed to a myeloid disease; however, both groups 
did demonstrate the emergence of T cell leukemia in 
a small number of mice, indicated by elevated levels 
of CD4+;CD8+ cells in the bone marrow and spleen. 
Taken together, these findings suggest that time-limited 
PI3Kδ inhibition delays mortality due to Shp2-induced 
leukemia, but does not alter the ultimate course of disease. 
These findings imply that PI3Kδ activity resumes after 
termination of treatment and that continued inhibition may 
be needed for optimal treatment of disease.
DISCUSSION
We previously found that genetic and pharmacologic 
inhibition of PI3K p110δ in vitro normalizes 
hypersensitivity to GM-CSF and reduces GM-CSF-
stimulated hyperproliferation of GOF Shp2-expressing 
murine and human cells [3]. Herein, we now demonstrate 
that in vivo inhibition of PI3K p110δ increases the survival 
of GOF Shp2-expressing mice. One notable observation 
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Figure 1: PI3K p110δ inhibition in vivo decreases splenomegaly and promotes myeloid cell maturation. A. The spleen to 
body weight ratio of mice at the end of 21 days of treatment, n = 7 per group, *p = 0.03 comparing PI3Kδ inhibitor-treated mice to vehicle-
treated mice, statistical analyses performed by unpaired, two-tailed, Student’s t-test. B. Number of colonies formed in methylcellulose 
colony forming assays, shown as a percentage of total colonies at maximum GM-CSF concentration. Bone marrow LDMNCs were 
collected and plated in triplicate per each concentration of GM-CSF. Colonies were counted 7 days after plating. C. Average percentage 
of Lin-Sca1+Kit+ (LSK) cells in bone marrow (BM), spleen (SP), and peripheral blood (PB), n = 7 per group, *p = 0.026 comparing LSK 
cells in the bone marrow of PI3Kδ inhibitor-treated mice to vehicle-treated mice, statistical analyses performed by unpaired, two-tailed, 
Student’s t-test. D. Average percentage of bone marrow T cells (CD4+, CD8+), B cells (B220+), and myeloid cells (Gr1+, Mac1+) gated on 
live events, n = 7 per treatment group. E. Average percentage of spleen T cells (CD4+, CD8+), B cells (B220+), and myeloid cells (Gr1+, 
Mac1+) gated on live events, n = 7 per treatment group. F. Average percentage of peripheral blood T cells (CD4+, CD8+), B cells (B220+), 
and myeloid cells (Gr1+, Mac1+) gated on live events, n = 7 per treatment group, *p = 0.05 comparing the percentage of myeloid cells in the 
peripheral blood of PI3Kδ inhibitor-treated mice to vehicle-treated mice, statistical analyses performed by unpaired, two-tailed, Student’s 
t-test. G. Representative flow cytometry diagrams showing Mac1 brightness in the peripheral blood of vehicle-treated and PI3Kδ inhibitor-
treated mice. H. Average Mac1 mean fluorescent intensity (MFI) in peripheral blood, n = 7 per group, *p = 0.0029 comparing PI3Kδ 
inhibitor-treated to vehicle-treated mice, statistical analyses performed by unpaired, two-tailed, Student’s t-test.
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Figure 2: PI3Kδ inhibitor-treated mice had significantly prolonged survival compared to vehicle-treated mice. A. 
Kaplan-Meier survival curve of days elapsed from start of treatment until death, n = 15 per treatment group, *p = 0.0092 comparing survival 
after treatment for PI3Kδ inhibitor-treated mice and vehicle-treated mice, statistical analyses performed by log-rank (Mantel-Cox) test. B. 
Average WBC count (K/uL) in peripheral blood of mice. C. Average spleen to body weight percentage at the time of death. D. Average 
WBC count (K/uL) in peripheral blood at the time of death. E. Percentage of bone marrow T cells (CD4+, CD8+), B cells (B220+), and 
myeloid cells (Gr1+, Mac1+) at the time of death, gated on live events. F. Percentage of spleen T cells (CD4+, CD8+), B cells (B220+), and 
myeloid cells (Gr1+, Mac1+) at the time of death, gated on live events.
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was increased peripheral blood terminally differentiated 
myeloid cells (Gr1+Mac1+) in the PI3Kδ inhibitor-treated 
animals (Figure 1F). One potential explanation for this 
observation is the recently-appreciated role of PI3K p110δ 
in regulatory T cell function with the resulting disruption 
of the protective tumor cell microenvironment and 
peripheral distribution of tumor cells upon PI3K p110δ 
inhibition [7]. In the context of this JMML model, it is 
possible that PI3K p110δ inhibition leads to redistribution 
and increased differentiation of mutant myeloid cells. 
In both the vehicle- and PI3Kδ inhibitor-treated 
animals, we observed increased peripheral blood WBC 
counts that temporally preceded a precipitous drop in 
survival (Figures 2A and 2B). The WBC spike in the 
PI3Kδ inhibitor-treated animals was more pronounced 
than that observed in the vehicle-treated group (Figure 
2B). One possibility accounting for this difference is that 
we simply “missed” a similarly high spike in the vehicle-
treated mice, which might have occurred between the 18 
week and 24 week scheduled blood draws (Figure 2B). 
An alternative explanation is that treatment with the 
PI3K p110δ inhibitor allowed animals to tolerate higher 
circulating WBC counts before succumbing to disease.
As the armamentarium of molecularly targeted 
therapies continues to grow, potential application to 
difficult-to-treat diseases such as JMML is a valuable 
priority. Previous work conducted in the Braun lab 
demonstrated that treatment of GOF Kras- and GOF 
Nras-expressing mice with the pan-PI3K inhibitor, GDC-
0941, or the allosteric Akt inhibitor, MK-2206, effectively 
ameliorated hyperactive Ras-induced disease [8]. The 
effectiveness of single pathway inhibition is likely limited, 
as drug resistance to PI3K/Akt inhibition can develop 
due to aberrant upregulation of the Ras-Erk pathway. 
However, an analysis of clinical trials found that patients 
receiving Ras/MEK/Erk pathway inhibitors combined 
with pan-PI3K inhibitors commonly experienced toxic 
adverse effects [9]. The differential and potentially more 
limited side effect profile of PI3Kδ inhibition compared 
to pan-PI3K inhibition [7, 10] may provide a therapeutic 
window to simultaneously target both the Ras-Erk and 
PI3K-Akt pathways in the treatment of JMML. There is a 
clear need for improved chemotherapeutic treatments for 
JMML, as the current treatment options are limited with 
only variable efficacy. This work supports the rationale of 
using PI3Kδ inhibitors in the treatment of patients with 
JMML and possibly other myeloid cell malignancies.
MATERIALS AND METHODS
Preparation of PI3Kδ inhibitor
A solution of 0.5% w/v methylcellulose (Sigma) and 
0.1% v/v Tween-80 (Sigma) was made in water. Using 
this solution, a stock of 7.5mg/mL of GS-9820 (provided 
by Gilead Sciences, Inc.) was made, aliquoted into 1mL 
aliquots, and stored at 4°C during the 21 days of treatment. 
Prior to each dosing, the necessary amount of drug and 
vehicle were brought to room temperature and mixed 
thoroughly. Mice were dosed 30mg/kg PO BID. 
Animal husbandry
Mice with a conditional mutant Shp2 allele, E76K, 
have been previously described [6]. Mice were housed 
and bred in accordance with the Institutional Animal Care 
and Use Committee of the Indiana University School of 
Medicine. Expression of the E76K mutation and LysMcre 
were confirmed by genotyping.
Colony forming assays
Ficoll-purified LDMNCs from bone marrow and 
spleen of mice were plated into methylcellulose-based 
assays with increasing concentrations of GM-CSF as 
previously described [11]. 
Flow cytometry/MFI
Cell suspensions were incubated for 5 minutes 
with 10% rat serum (MP Biomedicals) and 0.2% BSA 
(Roche) in PBS, then stained for 30 minutes at 4°C with 
biotinylated lineage markers (Mac1, Gr1, CD4, CD8, 
B220, Ter119, IL7Rα, CD19, and CD3 with streptavidin 
PerCPcy5.5 as secondary), anti-Sca1-PE, anti-cKit-APC, 
anti-Gr1-FITC, anti-Mac1-APC, biotinylated anti-CD4 
and anti-CD8 (with streptavidin APC as secondary), and/
or anti-B220-PE (eBioscience and BD Biosciences). The 
analyzer used for flow cytometry was the BD LSR II and 
data was analyzed using CellQuest.
Complete blood counts
Peripheral blood was collected from the saphenous 
vein of mice and complete blood counts were measured 
using a Hemavet 950 (Drew Scientific Group).
Statistical calculations
GraphPad was used to perform the unpaired, two-
tailed, Student’s t-tests and log-rank test.
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